1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

NextCell Pharma and Fujifilm Irvine Scientific enter strategic collaboration

23 May 2025
Admin
News Article

NextCell Pharma and Fujifilm Irvine Scientific enter strategic collaboration

NextCell Pharma and Fujifilm Irvine Scientific Announce Strategic Collaboration to Advance MSC-Based Cell Therapy Solutions
Stockholm

Sweden — May 2025 — NextCell Pharma AB (NextCell), a clinical-stage cell therapy company, has announced a strategic collaboration with Fujifilm Irvine Scientific Inc., a global leader in cell culture solutions. The partnership aims to integrate their respective expertise in mesenchymal stromal cells (MSCs) and life science raw materials to support researchers and developers in the cell therapy field.
Collaboration Highlights

Objective: Deliver an integrated solution combining:

o Standardised MSC products
o Optimised cell culture media
o Cryopreservation solutions

Target Users: Researchers and developers in cell and gene therapy, regenerative medicine, and related fields

Background and Progress

In 2024, NextCell expanded its product portfolio by developing a research-use-only umbilical cord MSC product, manufactured using its proprietary in-house expertise for the commercial market.

Building on this development, NextCell is now collaborating with Fujifilm to:
• Combine its MSC product with Fujifilm’s MSC-optimised media
• Leverage Fujifilm’s cryopreservation technologies
• Deliver a comprehensive cell therapy toolkit for scientific and industrial use

Benefits of the Joint Offering

This partnership is expected to provide the cell therapy ecosystem with:
• Standardised, high-quality MSC reference material
• Optimised media and cryopreservation solutions for efficient MSC culture and cold storage
• A reliable reference system for therapy development and validation

Executive Commentary

“We have worked closely together to develop this business relationship and are proud to be able to announce this new opportunity to our shareholders,” said Dr Lindsay Davies, Chief Scientific Officer at NextCell.
“This is a new business venture for NextCell, and we are excited to collaborate with Fujifilm, combining our expertise to build a strong partnership for the future,” added Mathias Svahn, CEO of NextCell.

About NextCell Pharma AB

NextCell is a clinical-stage cell therapy company focused on developing ProTrans, a patent-protected platform based on allogeneic mesenchymal stromal cells (MSCs) derived from umbilical cord tissue.

ProTrans uses a proprietary selection algorithm to deliver optimised cells tailored to specific disease indications.
About Fujifilm Irvine Scientific Inc.

Fujifilm Irvine Scientific is a global leader in the development of high-quality cell culture media and solutions for the life science and medical sectors, with over 50 years of industry experience.

The company is recognised for its commitment to innovation and its role in advancing fields such as cell and gene therapy.